REPLIGEN CORP Cash and Restricted Cash
REPLIGEN CORP (RGEN) had Cash and Restricted Cash of $608.81 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-29
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $608.81M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $584.64M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $566.02M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $748.75M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $608.81M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $584.64M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $566.02M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $748.75M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $708.86M 10-Q · filed 2026-07-29 |
| 2025-03-31 | $697.23M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $757.36M 10-Q · filed 2026-07-29 |
| 2024-09-30 | $783.96M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $809.15M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $780.62M 10-Q · filed 2025-04-29 |
| 2023-12-31 | $751.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | $630.78M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $603.66M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $516.61M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $523.46M 10-K · filed 2026-02-26 |
| 2022-09-30 | $573.36M 10-Q/A · filed 2024-11-18 |
| 2022-06-30 | $596.51M 10-Q/A · filed 2024-11-18 |
| 2022-03-31 | $584.64M 10-Q/A · filed 2024-11-18 |
| 2021-12-31 | $603.81M 10-K · filed 2025-03-14 |
| 2021-09-30 | $621.10M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $734.33M 10-Q · filed 2022-08-02 |
| 2021-03-31 | $711.32M 10-Q · filed 2022-04-27 |
| 2020-12-31 | $717.29M 10-K/A · filed 2024-11-18 |
| 2020-09-30 | $553.30M 10-Q · filed 2021-10-28 |
| 2020-06-30 | $560.36M 10-Q · filed 2021-07-27 |
| 2020-03-31 | $538.57M 10-Q · filed 2021-05-04 |
| 2019-12-31 | $537.41M 10-K · filed 2023-02-22 |
| 2019-09-30 | $522.43M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $217.82M 10-Q · filed 2020-07-30 |
| 2019-03-31 | $196.13M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $193.82M 10-K · filed 2022-02-17 |
| 2018-09-30 | $190.30M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $175.61M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $173.88M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $173.76M 10-K · filed 2021-02-24 |
| 2017-09-30 | $159.67M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $142.66M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $130.11M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $122.68M 10-K · filed 2020-02-26 |
| 2015-12-31 | $54.54M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |